P16-23| Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice

T Imakura - search.ebscohost.com
B Conclusions b: Sarcopenia predicted chemotherapy-triggered ILD exacerbation and OS in
patients with ILD-complicated NSCLC, suggesting its utility in determining treatment …
相关文章 所有 2 个版本

Computational Drug Repositioning Approach Identifies Polo-Like Kinase Inhibitors as Potential Therapeutics for Pulmonary Fibrosis

T Imakura, S Sato, K Koyama, H Ogawa… - … : ANIMAL AND CELL …, 2022 - atsjournals.org
[Rationale] Recently, the drug repositioning has become one line of scientific approach to
develop an effective drug. The aim of this study was to identify therapeutic options for …
相关文章
[HTML] springer.comFull View

[HTML][HTML] A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis

T Imakura, S Sato, K Koyama, H Ogawa, T Niimura… - Respiratory …, 2023 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with few
effective therapeutic options. Recently, drug repositioning, which involves identifying novel …
被引用次数：3 相关文章 所有 16 个版本

P16-6| Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model

H Kawano - search.ebscohost.com
Abstract P16-8: Cut-off points for step count to predict all-cause mortality in patients with
idiopathic pulmonary fibrosis 1 Department of Rehabilitation, Inoue Hospital, Japan, 2 …
相关文章

P16-36| A LCK-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-B production in regulatory T cells

K Kagawa - search.ebscohost.com
After administration of ferric citrate, the accumulation of calcium phosphate microliths and
the induction of COX-2 were significantly reduced in lung of Npt2b SP-/-sp mice. P16-38 …
相关文章 所有 2 个版本

The impact of Sarcopenia on the efficacy of PD-1 inhibitors in Non-Small Cell Lung Cancer and potential strategies to overcome resistance

Z Liu, T Lei, Y Guo, C Zheng - Frontiers in Pharmacology - frontiersin.org
Recent studies have revealed that sarcopenia can adversely affect the efficacy of PD-1
inhibitors in the treatment of non-small cell lung cancer (NSCLC). PD-1 inhibitors are …
相关文章

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer

Y Wang, L Wu, Y Yao, G Lu, L Xu, J Zhou - Cancer Letters, 2018 - Elsevier
The prognosis of small cell lung cancer (SCLC) is poor despite its good initial response to
chemotherapy. Polo-like kinase 1 (PLK1) is a crucial mitotic regulator that is overexpressed …
被引用次数：18 相关文章 所有 3 个版本
[HTML] nih.gov

Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

R Ferrarotto, R Goonatilake, S Young Yoo, P Tong… - Clinical Cancer …, 2016 - AACR
Purpose: To identify new therapeutic targets for non–small cell lung cancer (NSCLC), we
systematically searched two cancer cell line databases for sensitivity data on a broad range …
被引用次数：47 相关文章 所有 7 个版本

Polo-like kinase inhibitors

T Ichikawa, SW Kaldor - US Patent 8,026,234, 2011 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
40219644&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
被引用次数：1 相关文章 所有 4 个版本

Polo-like kinase inhibitors

SX Cao, V Feher, T Ichikawa, B Jones… - US Patent …, 2012 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
40219644&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
被引用次数：12 相关文章 所有 4 个版本